Shots:
- The US FDA has granted 510(k) clearance to the Salix Coronary Plaque module for the detection & quantification of coronary artery plaque; Salix is available since Jul 2025 in the US
- Also, Artrya is partnering with major US hospitals for the upcoming SAPPHIRE study, utilizing Salix Coronary Plaque module, plus it has signed a commercial deal with Tanner Health for Salix Coronary Anatomy platform in Jul 2025, while integration with Northeast Georgia Health & Cone Health is underway
- Salix Coronary Plaque module provides near real-time, point-of-care plaque & stenosis assessment for CCTA pts & is integrated with the Salix Coronary Anatomy platform to deliver results in under 10mins. without switching multiple systems
Ref: Artrya | Image: Artrya| Press Release
Related News:- Myra Vision Receives FDA Conditional IDE Approval for Calibreye TGT System to Treat Glaucoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
